Medical Specialty >> Gynecology
Doctors Aren’t Promoting Breastfeeding’s Cancer-Protection Benefit
2:00 PM CST.
Read article
- AHA: 3 Things to Know About Cholesterol
- AHA: Heart Attacks More Common Now in Younger People, Especially Women
- Mammograms Do Save Lives: Study
- AHA: Age, Race Are Leading Predictors of Heart Attacks in Pregnant Women
JOURNAL UPDATE
Denosumab Promising for TDT-Induced Osteoporosis Treatment
12:00 PM CST. Higher percentage increase of L1 to L4 and wrist bone mineral density with DMN, reduction in pain- Progress Toward Goals in Global Health Is Slowing
- Soy Feeding in Infancy Linked to Menstrual Pain in Blacks
- CDC: Increases in Yoga, Meditation for Children in 2012-2017
MONTHLY JOURNAL SUMMARY
October 2018 Briefing - OBGYN & Women’s Health
November 01, 2018. The Monthly Journal Summary is a single article covering the most important journal articles published in the previous 30 days.
FEATURED ARTICLES
Rucaparib Maintenance Therapy Improves PFS in Platinum-sensitive Ovarian Cancer - The ARIEL3 Trial
Robert L. Coleman, MD.
Professor Robert L. Coleman M.D., FACOG, FACS discusses the implications of data from the Phase 3 ARIEL3 trial of the novel PARP inhibitor rucaparib as maintenance therapy in patients with platinum-sensitive ovarian cancer. Professor Coleman is the Vice Chair of Clinical Research in the Department of…
Characterization of patients with ovarian carcinoma who respond to the PARP inhibitor rucaparib
Elizabeth M. Swisher, MD.
Dr. Elizabeth M. Swisher comments on the implications of new data from the ARIEL2 trial, an ongoing Phase 2 trial of the novel PARP inhibitor rucaparib in relapsed, high-grade serous or endometrioid ovarian cancer. The new results offer an important insight into the genetic mechanisms behind tumor sensitivity…
Bevacizumab for breast cancer: FDA grants a stay of execution
Dr. Alberto De la Guerra.
The Food and Drug Administration has after repeated delays proposed removing metastatic breast cancer as an indication from the Avastin label. The proposal is being contested by Roche/Genentech, the drug’s maker. In this article we review the evidence for and against this decision.
MEDICAL FOCUS
Breast cancer
By Tamer M. Fouad, M.D. Breast cancer is a cancer that starts in the cells of the breast. Worldwide, breast cancer is the second most common type of cancer after lung cancer (11.9%…
DISCUSSION
RE: Investigational Topical Minocycline Gel for Acne Advances to Phase III Development
By MrRobinGreat articles. learnt a lot from it.
